About neupogen


Your doctor will take you through the things you need to consider when preparing to take Neupogen®. Further information is also available in the Neupogen® Patient Information Leaflet.
Do not use Neupogen®:
if you are allergic to filgrastim or any of the other ingredients of this medicine (sodium acetate, sorbitol (E420), polysorbate 80, water for injections).
Please tell your doctor before starting treatment if you have:
sickle cell anaemia, as Neupogen® may cause sickle cell crisis.
an allergy to natural rubber (latex). The needle cover on the syringe may be made from a type of natural rubber and may cause allergic reactions.
osteoporosis (bone disease).
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Take special care with other products that stimulate white blood cells: Neupogen® is one of a group of products that stimulate the production of white blood cells. Your healthcare professional should always record the exact product you are using.
Pregnancy and breast-feeding:
Neupogen® has not been tested in pregnant or breast-feeding women. Neupogen® is not recommended during pregnancy.
It is important to tell your doctor if you:
are pregnant or breast-feeding;
think you may be pregnant; or
are planning to have a baby.
If you become pregnant during Neupogen® treatment, please inform your doctor.
Unless your doctor directs you otherwise, you must stop breast feeding if you use Neupogen®.
Driving and using machines:
Neupogen® may have a minor influence on your ability to drive and use machines. This medicine may cause dizziness. It is advisable to wait and see how you feel after taking Neupogen® and before driving or operating machinery.


Neupogen® (filgrastim). Patient Information Leaflet. [Available at: www.medicines.ie/medicines/list/all/page-1/per-page-25?query=neupogen]

This site is intended for patients in Ireland who are being treated with an Amgen® product and for Irish Healthcare Professionals (HCPs).

I am a member of the public
IE-CBU-0820-00002 August 2020